#France #Lyon #Antibody Therapies #genOway #Fcγ receptors

Revolutionizing Antibody Therapy Predictions

In a groundbreaking study published in Science Immunology, genOway has introduced its innovative mouse model known as genO-hFcγR, aimed at transforming the prediction of antibody therapies in humans. This new model addresses significant challenges in the current framework of antibody therapy development, particularly concerning the humanization of Fcγ receptors—vital proteins on immune cells that guide critical immune functions such as antibody-mediated cell killing and inflammation.

Historically, many promising drug candidates have faced unfortunate failures during clinical trials, with most of these failures attributed to the discrepancies between standard lab mouse models and human responses. Incompatibilities in Fcγ receptor structures can yield misleading efficacy results and overlook potential safety risks, leading to expensive failures in late-stage testing. Consequently, this hampers patients' access to new therapies that can significantly impact their health outcomes.

A New Benchmark in Preclinical Research

The genO-hFcγR mouse model, incorporating humanized Fcγ receptors, allows researchers to enhance the predictive accuracy regarding the effectiveness and safety of therapeutic antibodies intended for human use. This model offers the ability to thoroughly evaluate various antibody candidates, measure their efficacy in targeting specific immune cells, and gauge their capacity to decelerate disease progression. Such advancements provide researchers with critical insights to make informed decisions and accelerate the drug development process.

The development of the genO-hFcγR model required a sophisticated and collaborative effort from an international consortium of biopharmaceutical partners. Key players included genOway from France, argenx from Belgium, known for its Fc engineering expertise, and Innate Pharma from France, recognized for its pioneering work in natural killer cell-based immunotherapies. The collective knowledge and resources of these organizations culminated in the successful establishment and validation of the model.

The VIB-Ghent University in Belgium also played a pivotal role in this project, mapping the expression and regulation of Fc receptors. This collaborative initiative not only contributed to the scientific community's understanding of human diseases but also set a new standard for preclinical research methodologies.

A Solution for the Scientific Community

The genO-hFcγR model builds on a previous mouse model created by genOway and its scientific partners, which humanized multiple FcγR genes in 2008. Following its introduction to the academic sphere in 2024, this new model has been deployed to promote preclinical programs among biopharmaceutical companies and non-profit organizations, including global health initiatives like the Gates Foundation.

In summary, genOway's innovative approach through the genO-hFcγR mouse model is not just a step forward in enhancing the predictability of antibody therapies; it significantly impacts the speed and efficiency of clinical trials. By bridging the gap between preclinical findings and clinical success, genOway is poised to contribute to the development of effective treatments for cancer, inflammatory diseases, and infections. For more information about this revolutionary model, interested parties can visit genOway’s official website and access their detailed publication on the study.